15th International Adenovirus Meeting

Dear Colleagues,

Adenoviruses can cause mild health problems, such as acute respiratory, gastrointestinal, and ocular infections, but have no oncogenic potential in humans. Nevertheless, they can cause severe, even life-threatening, pathologies in immunosuppressed individuals. No efficient treatment for adenovirus infections has been approved so far. Besides humans, adenoviruses can also infect domestic animals, resulting in economic losses. However, adenoviruses represent exceptional candidates for wide-ranging therapeutic applications, from vectors for gene therapy to oncolytics for cancer treatments. The first ever commercial gene therapy medicine was based on a recombinant adenovirus vector, while most recently, adenoviral vectors have proven critical as vaccine platforms in effectively controlling the global coronavirus pandemic. Besides being used in therapeutic approaches, adenoviruses have also been popular model systems for studying viral entry, transcription and replication of the DNA genome, mRNA splicing, the expression of proteins, virus assembly, cell cycle control, cellular growth, the transformation of cells in vitro, and tumorigenesis.

The exchange of ideas and information among scientists working in all aspects of adenovirus biology and applications is fundamental to advance our ability to fight against adenovirus-induced disease, and to repurpose the virus as an efficient tool in biomedicine. Therefore, for this Special Issue, we welcome the most recent advances in adenovirus research in any paper format, including short and regular original articles and reviews. For participants of the 15th International Adenovirus Meeting in Croatia (https://event.fourwaves.com/iam2023/pages), a 20% discount on Article Processing Charges will be applied.

Dr. Dragomira Majhen
Prof. Dr. Alan Parker
Prof. Dr. David T. Curiel
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Viruses is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.